Colorectal Cancer Clinical Trial
— EDICTOfficial title:
Clinical and Biological Effects of a Preoperative Exercise Programme in Colorectal Tumour and Skeletal Muscle Tissues (Exercise inDuced Changes In Colorectal Cancer Tissues)
Verified date | March 2018 |
Source | The Royal Bournemouth Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot study looks to explore the biological effects of exercise on cancer and muscle cells using a two week exercise program (HIThigh intensity training) on 20 patients with newly diagnosed and operable colorectal cancer following diagnosis and prior to surgery. Maximal oxygen uptake will also be measured. The aim of this pilot is to assess the feasibility of recruiting participants to and carrying out a two week preoperative exercise program in patients with colorectal cancer.
Status | Completed |
Enrollment | 16 |
Est. completion date | October 30, 2017 |
Est. primary completion date | September 19, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Colorectal cancer confirmed by histology - Considered fit for surgery by surgical and anaesthetic team - Considered fit for physical activity programme by MDT - Age = 18 years - BMI = 26 kg/m2 - Not pregnant - Non obstructing cancer - Able to provide written informed consent - Patients not having neoadjuvant chemotherapy Exclusion Criteria: - Receiving hormone therapy - Patients with diabetes - Patients currently on either a dietary or exercise programme reflective of the World Cancer Research Fund Guidelines. - Cardiac or renal impairment - Excessive use of laxatives - History of eating disorders - Patients with inflammatory bowel disorders/coeliac - Strong family history/polyposis (i.e. more than one 1st degree relative <55yrs) - Patients with previous or concurrent malignancies |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Royal Bournemouth Hospital | Bournemouth | Dorset |
United Kingdom | Poole Hospital | Poole | Dorset |
Lead Sponsor | Collaborator |
---|---|
The Royal Bournemouth Hospital |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess the feasibility of carrying out a two week preoperative exercise program in patients with colorectal cancer and assess the effects of preoperative exercise on the proliferation of colorectal cancer cells | To assess the feasibility of carrying out a two week preoperative exercise program in patients with colorectal cancer and to assess the effects of preoperative exercise on the proliferation of colorectal cancer cells by measuring the change in the percentage of cells staining positive for Ki67 (a measure of cell proliferation). | 1 year | |
Secondary | Changes in molecular markers for the effects of exercise and/or diet on AMPK/ mammilian target of rapamycin signalling pathway | Measuring changes in molecular markers for the effects of exercise and/or diet on AMPK/mTOR signalling pathway (phosphorylated 4EBP1 (P4EBP1), phosphorylated protein kinase B (PPKB/AKT), and phosphorylated AMPK (PAMPK). | 12 weeks | |
Secondary | Changes in AKT expression normal colonic tissue | Measuring changes in AKT expression normal colonic tissue - Intensity of AKT1/AKT2 staining, or AKT phosphorylation, a marker of insulin receptor signalling in cells. | 12 weeks | |
Secondary | Assessing Apoptosis index | Assessing Apoptosis index - Percentage of tumour cells staining positive for DNA fragmentation, a marker of cells undergoing apoptosis and therefore cell death. | 12 weeks | |
Secondary | Changes in molecular markers that may mediate or modify exercise/dietary effects in tumour tissues | Measuring changes in molecular markers that may mediate or modify exercise/dietary effects in tumour tissues (IR, IGF1R, p53 and its transcriptional target p21, ER, progesterone receptor, tumor necrosis factor-alpha converting enzyme and TIMP3). | 12 weeks | |
Secondary | Assessing gene expression profiles | Assessing gene expression profiles focusing on gene associated with insulin resistance. | 12 weeks | |
Secondary | Assessing the 11 gene signature | Assessing the 11 gene signature that help to predict maximal oxygen uptake gain in patients before and after exercise | 12 weeks | |
Secondary | Blood methylation profiles. | Blood methylation profiles. | 12 weeks | |
Secondary | Cortisol levels | Cortisol levels to evaluate levels of biological stress. | 12 weeks | |
Secondary | Postoperative complications up to 30 days postoperatively | Postoperative complications up to 30 days postoperatively | 30 days post op | |
Secondary | Moderator variables | Moderator variables including state of motivational readiness for exercise, weight change, depression and anxiety | 12 weeks | |
Secondary | Irisin levels | Irisin levels before and after exercise | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Not yet recruiting |
NCT05775146 -
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
|
Phase 2 | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 |